Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
RNATICS Logo
RNATICS CB Rank
892696
Heat Score
57
RNATICS develops RNA therapeutics targeting disease-causing RNAs in tissue macrophages, offering significant therapeutic opportunities.
Founded
obfuscation
Private Martinsried, Bayern, Germany1-10 rnatics.com
Biotechnology
Therapeutics
Overview

RNATICS
Heat Score
57

Growth Score
pts
in past quarter
Heat Score 57
-9 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About RNATICS

CB Rank
892696
RNATICS develops RNA therapeutics targeting disease-causing RNAs in tissue macrophages, offering significant therapeutic opportunities.
Founded
obfuscation
Private Martinsried, Bayern, Germany1-10 rnatics.com
Biotechnology
Therapeutics

Key People

Details

Legal Name rnatics GmbH
Operating Status Active
Company Type For Profit
Founders  Klaus F. Rabe, Stefan Engelhardt, Thomas F. Frischmuth
About the Company

RNATICS develops RNA therapeutics that target disease-causing RNAs in tissue macrophages. This approach provides significant therapeutic opportunities for various diseases, including COVID-19. The company has received recognition for its innovative RNA therapeutic solutions and has been awarded grants for clinical development. RNATICS' unique

macrophage-targeted delivery technology enhances the effectiveness of their treatments by focusing on specific cell surface receptors.

Contact Email info@rnatics.com
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

RCS-21
An inhaled RNA therapeutic targeting microRNA-21 in lung macrophages to reduce inflammation and fibrosis in pulmonary diseases.
Macrophage-Targeted RNA Therapeutics Platform
A proprietary carbohydrate-coupling technology for delivering RNA therapeutics specifically to tissue resident macrophages across multiple organs.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 3 Contacts 1

Employee Profiles

News
Technology
View Tech Report

Monthly Web Visits

67
3.08%
 in past month

IT Spend

$168.9KThis year, RNATICS is projected to spend $168.9K on IT, according to Aberdeen.
Sub-Organizations
Frequently Asked Questions

Where is RNATICS's headquarters? RNATICS is located in Martinsried, Bayern, Germany.Who are RNATICS's competitors? Alternatives and possible competitors to RNATICS may include Alnylam Pharmaceuticals, Ractigen Therapeutics, and  Aro Biotherapeutics.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(55a1db1 1)
|